Skip to main content
SpringerLink
Log in
Book cover

Diffuse Malignant Mesothelioma pp 125–139Cite as

Therapy

  • Chapter
  • First Online:

  • 894 Accesses

Abstract

Malignant mesotheliomas are rare but aggressive neoplasms that arise from the pleural or peritoneal lining. Most often triggered by asbestos exposure, there is a long latency period between exposure and the clinical manifestations of the disease. The precise role of which surgical approach to utilize remains controversial, even in those patients who have limited disease, and chemotherapy combinations have had only modest efficacy at prolonging survival. Radiation therapy can often be added as part of a multimodality approach in selected patients, as well as offer a palliative benefit in controlling pain. It is hoped that advances in understanding the underlying molecular drivers will eventually lead to more efficacious therapeutic alternatives.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Weill H, Hughes JM, Churg AM. Changing trends in US mesothelioma incidence. Occup Environ Med. 2004;61:438–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79(3–4):666–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–6.

    PubMed Central  PubMed  Google Scholar 

  4. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723–31.

    Article  CAS  PubMed  Google Scholar 

  5. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, Vaporciyan AA, Walsh GL, Sabloff BS, Broemeling LD, Stevens CW, Pisters KM, Podoloff DA, Macapinlac HA. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg. 2005;129(6):1364–70.

    Article  PubMed  Google Scholar 

  6. Nakano T, Fujii J, Tamura S, Hada T, Higashino K. Thrombocytosis in patients with malignant pleural mesothelioma. Cancer. 1986;58(8):1699–701.

    Article  CAS  PubMed  Google Scholar 

  7. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367:1417–27.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Pilling J, Dartnell JA, Lang-Lazdunski L. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovasc Surg. 2010;58(4):215–9. doi: 10.1055/s-0029-1241029.

    Article  CAS  PubMed  Google Scholar 

  9. Rusch V, Baldini EH, Bueno R, et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J Thorac Cardiovasc Surg. 2013;145:909–10.

    Google Scholar 

  10. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–6, e1–3.

    Article  PubMed  Google Scholar 

  11. Sugarbaker DJ, Wolf AS, Chirieac LR, et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg. 2011;40:298–303.

    PubMed  Google Scholar 

  12. Sugarbaker DJ, Wolf AS. Surgery for malignant pleural mesothelioma. Expert Rev Respir Med. 2010;4:363–72.

    Article  PubMed  Google Scholar 

  13. Wolf AS, Richards WG, Tilleman TR, et al. Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg. 2010;90:949–56; discussion 56.

    Article  PubMed  Google Scholar 

  14. Rusch VW, Giroux D. Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg. 2012;1:438–48.

    PubMed Central  PubMed  Google Scholar 

  15. Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques for multimodality treatment of malignant pleural mesothelioma: extrapleural pneumonectomy and pleurectomy/decortication. Semin Thorac Cardiovasc Surg. 2009;21:132–48.

    Article  PubMed  Google Scholar 

  16. Sugarbaker DJ, Gill RR, Yeap BY, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145:955–63.

    Article  CAS  PubMed  Google Scholar 

  17. Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg. 2009;138:405–11.

    Article  PubMed  Google Scholar 

  18. de Graaf-Strukowska L, van der Zee J, van Putten W, et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura–a single institution experience with 189 patients. Int J Radiat Oncol Biol Phys. 1999;43:511–6.

    Article  PubMed  Google Scholar 

  19. Kutcher GJ, Kestler C, Greenblat D, et al. Technique for external beam treatment for mesothelioma. Int J Radiat Oncol Biol Phys. 1987; 13:1747–52.

    Article  CAS  PubMed  Google Scholar 

  20. Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045–52.

    Article  PubMed  Google Scholar 

  21. Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56:1319–26.

    Article  PubMed  Google Scholar 

  22. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and post-operative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006;1:289–95.

    Article  PubMed  Google Scholar 

  23. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84:1685–93.

    Article  PubMed  Google Scholar 

  24. Buduhan G, Menon S, Aye R, et al. Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2009;88:870–6.

    Article  PubMed  Google Scholar 

  25. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65(3):640–5.

    Article  PubMed  Google Scholar 

  26. Rice DC, Smythe WR, Liao Z, et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2007;69:350–7.

    Article  PubMed  Google Scholar 

  27. Chi A, Liao Z, Nguyen NP, Howe C, Gomez D, Jang SY, Komaki R. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. J Thorac Oncol. 2011;6(6):1132–41.

    Article  PubMed  Google Scholar 

  28. Bölükbas S, Eberlein M, Schirren J. Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol. 2012;7(5):900–5.

    Article  Google Scholar 

  29. Minatel E, et al. Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer 2013. http://dx.doi.org/10.1016/j.lungcan.2013.10.013.

  30. Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8(2):238–45.

    Article  PubMed  Google Scholar 

  31. Rosenzweig K. Current readings: improvements in intensity modulated radiation therapy for malignant pleural mesothelioma. Semin Thoracic Surg. http://dx.doi.org/10.1053/j.semtcvs.2013.10.004.

  32. de Graaf-Strukowska L, van der Zee J, van Putten W et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura–a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys. 1999;43:511–6.

    Article  PubMed  Google Scholar 

  33. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol. 1996;14(3):1007–17.

    CAS  PubMed  Google Scholar 

  34. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robins BWS. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17(1):25–30.

    CAS  PubMed  Google Scholar 

  35. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BW. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87(5):491–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007;6(2):404–17.

    Article  CAS  PubMed  Google Scholar 

  37. Thödtman R, Depenbrock H, Dumez H, Blatter J, Johnson RD, van Oosterom A, Hanauske A-R. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol. 1999;17(10):3009–16.

    Google Scholar 

  38. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14):2636–26.

    Article  CAS  PubMed  Google Scholar 

  39. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881–9.

    Article  PubMed  Google Scholar 

  40. Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naïve malignant pleural mesothelioma. J Clin Oncol. 2008;26(9):1465–71.

    Article  PubMed  Google Scholar 

  41. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Conte GD, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Soto Parra HJ, Santoro A. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24(9):1443–8.

    Article  CAS  PubMed  Google Scholar 

  42. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol. 2010;5(4):479–83.

    Article  PubMed  Google Scholar 

  43. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, Procopio A. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193(4):468–75.

    Article  CAS  PubMed  Google Scholar 

  44. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato III SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012;30(20):2509–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008;113(4):808–14.

    Article  CAS  PubMed  Google Scholar 

  46. Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol. 2014;19(4):601–6.

    Article  CAS  PubMed  Google Scholar 

  47. Nowak AK, Millward MJ, Creaney J, Francis RJ, Dick IM, Hasani A, van der Schaaf A, Segal A, Musk AW, Byrne MJ. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol. 2012;7(9):1449–56.

    Article  CAS  PubMed  Google Scholar 

  48. Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009;8(8):2221–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Krug LM, Kindler H, Calvert H, Manegold C, Tsao AS, Fennell D, Lubiniecki GM, Sun X, Smith M, Baas P. VANTAGE 014: Vorinostat (V) in patients with advanced Malignant Pleural Mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III, randomized, double-blind, placebo-controlled trial. Eur J Cancer. 2011;47(Suppl 2):2–3.

    Article  Google Scholar 

  50. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D. Phase II study of Belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009;4(1):97–101.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, Bains MS, Downey RJ, Ginsberg RJ. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788–95.

    Article  CAS  PubMed  Google Scholar 

  52. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117(1):54–65.

    Article  CAS  PubMed  Google Scholar 

  53. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel RA. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22(17):3451–7.

    Article  CAS  PubMed  Google Scholar 

  54. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, Snee M, O’Brien M, Thomas G, Senan S, O’Byrne K, Kilburn LC, Spicer J, Landau D, Edwards J, Coombes G, Darlison L, Peto J, for the MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–72.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237–42.

    Article  PubMed  Google Scholar 

  57. Markman M. Continued uncertainty regarding hyperthermic intraperitoneal chemotherapy in malignant peritoneal mesothelioma. J Clin Oncol. 2010;28(24):e418.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Center, Houston Methodist Hospital, 6445 Main Street Floor 21, 77030, Houston, TX, USA

    Eric Bernicker MD

  2. Department Thoracic Surgery, Houston Methodist Hospital, Houston, TX, USA

    Puja Gaur MD & Shanda H. Blackmon MD, MPH

  3. Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA

    Snehal Desai MD & Bin S. Teh MD

Authors
  1. Eric Bernicker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Puja Gaur MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Snehal Desai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bin S. Teh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shanda H. Blackmon MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Bernicker MD .

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, The University of Texas Medical Branch, Galveston, Texas, USA

    Timothy Craig Allen

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bernicker, E., Gaur, P., Desai, S., Teh, B., Blackmon, S. (2015). Therapy. In: Allen, T. (eds) Diffuse Malignant Mesothelioma. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2374-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2374-8_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2373-1

  • Online ISBN: 978-1-4939-2374-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation